Thursday, July 9, 2026

pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

cardiff, GB HQ
2000 Founded
25 Employees
Public company Type
BDRX · NYSE Ticker
Company details
Status
Public
HQ
cardiff, GB
Founded
2000
Employees
25
Programs
4
Drugs
5
Patents
2
Intelligence · Patents

Biodexa Pharmaceuticals patents

2 pharmaceutical patents indexed for Biodexa Pharmaceuticals. 1 expire within 24 months.

Biodexa Pharmaceuticals has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 7101863

    Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative

    Expires Mon Aug 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 6646120

    Dextran derivatives, preparation and medicinal applications

    Expires Mon Nov 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Biodexa Pharmaceuticals have?

2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Biodexa Pharmaceuticals patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.